PD-1 suppresses human CD38+ circulating Tfr cells and regulates humoral immunity

Background Anti-programmed cell death protein 1 (anti-PD-1) antibodies have achieved revolutionary success in cancer therapy. However, the impact of anti-PD-1 therapy on host humoral immunity in humans during cancer immunotherapy requires further investigation.Methods We evaluated immunoglobulin tit...

Full description

Saved in:
Bibliographic Details
Main Authors: Heng Zhang, Hui Zheng, Lin Guo, Ying Tong, Xiaolu Ma, Yanchun Wang, Renquan Lu, Cuncun Chen, Suhong Xie
Format: Article
Language:English
Published: BMJ Publishing Group 2025-01-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/1/e010026.full
Tags: Add Tag
No Tags, Be the first to tag this record!